Minodronic acid influences receptor activator of nuclear factor κB ligand expression and suppresses bone resorption by osteoclasts in rats with collagen-induced arthritis

References

• Trentham DE, Townes AS, Kang AH. Autoimmunity to type II collagen: an experimental model of arthritis. J Exp Med 1977;146: 857–68.
   Google Scholar
• Enokida M, Yamasaki D, Okano T, Hagino H, Mono Y, Teshima R. Bone mass changes of tibial and vertebral bones in young and adult rats with collagen-induced arthritis. Bone 2001;28:87–93.
   PubMedGoogle Scholar
• Yamane I, Hagino H, Okano T, Enokida M, Yamasaki D, Teshima R. Effect of minodronic acid (ONO-5920) on bone mineral density and arthritis in adult rats with collagen-induced arthritis. Arthritis Rheum 2003;48:1732–41.
   PubMed Web of Science ®Google Scholar
• Fukata S, Hagino H, Okano T, Yamane I, Kameyama Y, Teshima R. Effect of intermittent administration of human parathyroid hor-mone on bone mineral density and arthritis in rats with collagen-induced arthritis. Arthritis Rheum 2004;50:4060–9.
   PubMedGoogle Scholar
• Kameyama Y, Hagino H, Okano T, Enokida M, Fukata S, Teshima R. Bone response to mechanical loading in adult rats with collagen-induced arthritis. Bone 2004;35:948–56.
   PubMedGoogle Scholar
• Rogers MJ, Frith JC, Luckman SP, Coxon FP, Benford HL, Monk-konen J, et al. Molecular mechanisms of action of bisphosphonate. Bone 1999;24 Suppl 5:73S–9S.
   Google Scholar
• Wood, FD, Pearson CM, Tanaka A. Capacity of mycobacterial wax D and its subfractions to induce adjuvant in rats. Int Arch Allergy 1969;35:456.
   Web of Science ®Google Scholar
• Suzuki Y, Nishikaku M, Koga Y. Osteoclast-like cells in murine collagen induced arthritis. J Ftheumatol 1998;25:6:1154–60.
   Google Scholar
• Fujikawa Y, Shingu M, Torisu T, Itonaga I, Masumi M. Bone re-sorption by tartrate-resistant phosphate-positive multinuclear cells isolated from rheumatoid synovium. Br J Ftheumatol 1996;35: 213–7.
   Google Scholar
• Lubberts E, Oppers-Walgreen B, Pettit AR, van den Bersselaar L, Joosten LAB, Goldring SR, et al. Increase in expression of recep-tor activator of nuclear factor IcB at sites of bone erosion correlates with progression of inflammation in evolving collagen-induced ar-thritis. Arthritis Rheum 2002;46:3055–64.
   PubMedGoogle Scholar
• Kisimoto Y, Fukumoto S, Nishihara S, Mizumura H, Hirai K, Teshima R. Gene expression relevant to osteoclastogenesis in the synovium and bone marrow of mature rats with collagen-induced arthritis. Ftheumatology 2004;43:1496–1503.
   PubMedGoogle Scholar
• Morii H, Nishizawa Y, Taketani Y, Nakamura T, Itabashi A, Mizunuma H, et al. A randomized controlled trial with ONO-5920 (minodronate/YM529) in Japanese patients with postmeno- 24. pausal osteoporosis [abstract]. J Bone Miner Res 2002;17 Suppl 1: S471.
   Google Scholar
• Kim YH, Kim GS, Baek H. Inhibitory action of bisphosphonates on bone resorption dose not involve the regulation of FtANKL and 25. OPG expression. Experimental and Molecular Medicine 2002;34: 145–51.
   Google Scholar
• Uludag H. Bisphosphonates as a foundation of drug delivery to bone. Curr Pharm Des 2002;8:1929-44.26.
   Google Scholar
• Halasy-Nagy JM, Rodan GA, Reszka AA. Inhibition of bone re-sorption by alendronate and risedronate does not require osteo- clast apoptosis. Bone 2001;29: 553–59.27.
   Google Scholar
• Pan B, Farrugia NA, To LB, Findlay DM, Green J, Lynch K, et al. The nitrogen-containing bisphosphonate, zoledronic acid, influ-ences FtANKL expression in human osteoblast-like cells by acti- 28. vating TNF-a converting enzyme (TACE). J Bone Miner Res 2004;19:147–54.
   PubMed Web of Science ®Google Scholar
• Teitelbaum SL. Bone resorption by osteoclasts. Science 2000;289: 29. 1504–8.
   PubMedGoogle Scholar
• Gravallese EM. Bone destruction in arthritis. Ann Rheum Dis 2002;61 Supp1:84–06.30.
   Google Scholar
• Takayanagi H, Ezuka H, Juji T, Nakagawa T, Yamamoto A, Miyazaki T, et al. Involvement of receptor actinovator of nuclear factor IcB ligand/osteoclast differentiation factor in osteoclastogen- 31. esis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 2000;43:259–69.
   PubMed Web of Science ®Google Scholar
• Romas E, Bakharevski 0, Hards DK, Kartsogiannis V, Quinn JMW, Ryan PFJ, et al. Expression of osteoclast differentiation 32. factor at sites of bone erosion in collagen-induced arthritis. Arthri-tis Rheum 2000;43: 821–26.
   Google Scholar
• Goldring SR, Gravallese EM. Pathogenesis of bone erosions in rheumatoid arthritis. Curr Opin Ftheumatol 2000;12:195–99.
   PubMed Web of Science ®Google Scholar
• Azuma Y, Kaji K, Katogi R, Takeshita S, Kudo A. Tumor necrosis-a induces differentiation of and bone resorption by osteoclast. J 33. Biol Chem 2000;7: 4858–64.
   Google Scholar
• Fujimoto M, Hayashida K, Ochi T, Owaki H, Shimaoka Y, Oka-mura M, et al. Fluctuation of interleukin-1 and -6 activity in bone marrow serum in collagen-induced arthritis in rats. Biomed Res 1992;13: 243–51
   Google Scholar
• Suda T, Takahasi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999;20:345–57.
   PubMed Web of Science ®Google Scholar
• Zhang YH, Heulsmann A, Tondravia MH, Mukherjee A, Abu-Amer Y. Tumor necrosis factor-a (TNF) stimulates RANKL-induced osteodastogenesis via coupling of type 1 receptor and RANK signaling pathways. J Biol Chem 2001;276: 563–68.
   Google Scholar
• Tanahashi M, Koike J, Kawabe N, Nakadate-Matsusita T. Inhibi-tory effect of TRK-530 on rat adjuvant arthritis. Pharmacology 1998;56: 242–51.
   Google Scholar
• Cantatore FP, Acquista CA, Vincenzo P. Evaluation of bone turn-over and osteodastic cytokines in early rheumatoid arthritis treat-ed with alendronate. J Fthematol 1999;26:2318–23.
   Google Scholar
• Tanahashi M, Koike J, Kawabe N, Nakadate-Matsusita T. Inhibi-tory effect of TRK-530 on inflammatory cytokines in bone marrow of rats with adjuvant arthritis. Pharmacology 1998;56: 237–41.
   Google Scholar
• Zhao H, Sheuto T, Hirata G, Iwamoto Y. Aminobisphosphonate (YM175) inhibits bone destruction in rat adjuvant arthritis. J Orthop Sci 2000;5:397–403.
   PubMedGoogle Scholar
• Flora L. Comparative antiinflammatory and bone protective ef-fects of two diphosphonates in adjuvant arthritis. Arthritis Rheum 1979;22:340–6.
   PubMedGoogle Scholar
• Nakamura M, Ando T, Abe M, Kumagai K, Endo Y. Contrast between effects of aminobisphosphonates and nonaminobisphos-phonates on collagen-induced arthritis in mice. Br J Pharmacol 1996;119:205–12.
   Google Scholar
• Zwerina J, Hayer SH, Tohidast-Akrad M, Bergmeister H, Redlich K, Feige U, et al. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum 2004;50: 277–90.
   Google Scholar
• Volker V, Gunter E, Vanessa L, Karl-Heinz F, Sabine B, Carsten G, et al. Bisphosphonates pamidronate and zoledronic acid stimu-late osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun 2002;291:680–86.
   Google Scholar